MEDIFAST (MED)
(Delayed Data from NYSE)
$19.88 USD
+0.18 (0.91%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $19.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.88 USD
+0.18 (0.91%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $19.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum A VGM
Zacks News
Archer Daniels (ADM) Beats Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Archer Daniels' (ADM) Q4 results reflect gains from healthy product demand, robust crush margins, strength in the Nutrition segment and improved productivity.
5 Top DuPont-Assured Quality Stocks to Beat Volatility
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived the DuPont way.
Tyson Foods' (TSN) Capacity Expansion Aids, High Costs Persist
by Zacks Equity Research
Tyson Foods (TSN) is on track with capacity expansion and automation technology investments. Also, it is focused on higher protein production.
Procter & Gamble (PG) Beats on Q2 Earnings & Sales, Ups View
by Zacks Equity Research
Procter & Gamble's (PG) Q2 results gain from the rising demand for cleaning products due to the resurgence of COVID-19 cases, robust sales growth and pricing gains. Management raises the fiscal 2022 view.
Are These Consumer Staples Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kraft Heinz's (KHC) Operating Model & Pricing Efforts Solid
by Zacks Equity Research
Kraft Heinz (KHC) is committed to its operating model, which incorporates five key elements. Also, solid pricing initiatives are yielding.
Nu Skin (NUS) Shines on Solid Sales Leaders & Customer Network
by Zacks Equity Research
Nu Skin Enterprises (NUS) has been benefiting from its efforts to empower sales leaders and strengthen the customer base.
Campbell Soup (CPB) Focuses on Saving Efforts Amid High Costs
by Zacks Equity Research
Campbell Soup (CPB) has been gaining on its strategic priorities as well as saving efforts amid rising cost inflation.
Flowers Foods (FLO) Is Poised on Core Priorities, Solid Pricing
by Zacks Equity Research
Flowers Foods (FLO) has been gaining on its strategic priorities, such as developing its team, concentrating on brands, prioritizing margins and looking out for prudent mergers and acquisitions.
Is Medifast (MED) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.
What Makes Medifast (MED) a New Buy Stock
by Zacks Equity Research
Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are These Consumer Staples Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Helen of Troy (HELE) Q3 Earnings Beat, Fiscal 2022 View Up
by Zacks Equity Research
Helen of Troy (HELE) Q3 reflects strong consumer and retailer demand for the Housewares and Beauty segments aiding core sales and earnings.
Tyson Foods (TSN) Up More Than 20% in 6 Months: Will it Stay?
by Zacks Equity Research
Tyson Foods (TSN) is focused on higher protein production to cater to higher demand for protein-packed food. Also, robust demand in its retail core business lines is a driver.
Conagra (CAG) Q2 Earnings Lag Estimates, Sales Increase Y/Y
by Zacks Equity Research
Conagra Brands' (CAG) second-quarter fiscal 2022 results reflect lower earnings due to cost inflation. Management ups organic net sales view but keeps earnings per share guidance intact.
Lamb Weston (LW) Q2 Earnings Top Estimates, Sales Rise Y/Y
by Zacks Equity Research
Lamb Weston's (LW) second-quarter fiscal 2022 results reflect year-over-year sales growth on increased sales volumes and price/mix. However, earnings declined year over year.
Post Holdings (POST) Gains on Solid BellRing Brands & Buyouts
by Zacks Equity Research
Post Holdings (POST) is expanding its portfolio through strategic acquisitions. The company's BellRing Brands unit is gaining from strength in Premier Protein and Dymatize banners.
Mondelez's (MDLZ) Chipita Addition Boosts Snacks Portfolio
by Zacks Equity Research
Mondelez (MDLZ) is making prudent buyouts to drive growth. The buyout of Chipita strengthens MDLZ's snacking category.
Colgate (CL) Well Poised on Growth Strategies Amid Cost Woes
by Zacks Equity Research
Despite raw material cost inflation, Colgate's (CL) robust innovation and expansion plans are likely to drive growth in the long term.
Is Medifast (MED) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Here is how Medifast (MED) and SunOpta (STKL) have performed compared to their sector so far this year.
Medifast (MED) Gains on OPTAVIA Strength, SG&A Costs Rise
by Zacks Equity Research
Medifast (MED) has been gaining on strength of its OPTAVIA lifestyle solution and coaching support system, which was a major driver in the third quarter.
Should Value Investors Pick Medifast (MED) Stock Now?
by Vedika Agarwal
Is Medifast (MED) a great pick from the value investor's perspective right now? Read on to know more.
Medifast (MED) Raises View on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Medifast's (MED) third-quarter 2021 results reflect stellar earnings and revenues, courtesy of continued strength in OPTAVIA. Management raises earnings per share and revenue guidance for 2021.
Medifast (MED) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 21.92% and 1.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Factors to Consider as Medifast (MED) Gears Up for Q3 Earnings
by Zacks Equity Research
Medifast's (MED) third-quarter results are likely to reflect gains from the OPTAVIA lifestyle solution and coaching support system, though high costs are a concern.